Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Alpine Immune Sciences' stock. Their ALPN share price forecasts range from $11.00 to $25.00. On average, they predict the company's stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts.

Alpine Immune Sciences' stock was trading at $7.35 at the beginning of 2023. Since then, ALPN stock has increased by 34.7% and is now trading at $9.90.
View the best growth stocks for 2023 here.

Alpine Immune Sciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,150,000 shares, an increase of 8.5% from the April 30th total of 1,060,000 shares. Based on an average daily volume of 107,200 shares, the short-interest ratio is presently 10.7 days.
View Alpine Immune Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ALPN earnings forecast.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.14. The biotechnology company had revenue of $2.78 million for the quarter, compared to analyst estimates of $10.42 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 40.29% and a negative net margin of 245.92%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN).

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (7.80%), BlackRock Inc. (3.24%), BVF Inc. IL (1.79%), Geode Capital Management LLC (1.16%), State Street Corp (0.72%) and Renaissance Technologies LLC (0.69%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends.

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPN stock can currently be purchased for approximately $9.90.

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $474.90 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.